

*Contains Nonbinding Recommendations*

**Draft Guidance on Minoxidil**

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

**Active ingredient:** Minoxidil

**Form/Route:** Solution/Topical 2%

**Recommended study:** Request for Waiver of In vivo Bioequivalence Study Requirements

**Bioequivalence study recommendations:**

To qualify for a waiver of the in vivo bioequivalence (BE) study requirements under 21 CFR 320.22(b)(3), a generic minoxidil topical solution product must have the same active ingredient in the same concentration and dosage form as the reference listed drug product (RLD) and must not have an inactive ingredient or other change in formulation from the RLD that may significantly affect systemic or local availability.

All ingredients in the test and reference formulations are to be compared using the same units, either % w/w or % w/v.

For a topical drug product with inactive ingredients that differ from the RLD or are present in significantly different amounts [as permitted by the chemistry, manufacturing and controls regulations for abbreviated new drug applications, 21 CFR 314.94(a)(9)(v)], the regulation specifies that the applicant must identify and characterize the differences and provide information demonstrating that the differences do not affect the safety or efficacy of the proposed drug product.